Johnson & Johnson is ready to start trialing its Ebola vaccine in Africa, where Merck and NewLink are preparing to take theirs into Phase III. GlaxoSmithKline is also testing its jab there. But while thousands of healthcare workers have volunteered to participate in Ebola vaccine trials, the decision to mass-vaccinate against the disease is still up in the air.
Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.
Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.
The current Ebola outbreak may be starting to wane, but scientists agree they'll need a stockpile of vaccines to tackle the next one. And that means developing next-generation shots that can fight off multiple strains.
As the Disneyland measles outbreak continues to spread, some are pointing the finger at Merck, maker of the only U.S.-approved measles vaccine. But when it comes to encouraging the public to get vaccinated, there's a limit on how much the company can do, its R&D; chief says.
After creating a global specialty unit for its vaccines business and tapping a new development head last fall, Takeda now plans to drop a Phase II Diphtheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV) program in Japan to focus on markets where it can make a bigger splash.
The measles outbreak that began at Disneyland is spreading across California and beyond, and it's reigniting a heated debate over the anti-vaccination movement.
In July last year, GlaxoSmithKline submitted its malaria vaccine, RTS,S, for regulatory review by the European Medicines Agency. Because there are no existing malaria vaccines, Glaxo says that a vaccine to be used "alongside other measures such as bed nets and anti-malarial medicines" would be an advance in malaria control. However, a new study published Monday might have GSK rethinking the bed nets.
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.
The affordable meningitis A vaccine, MenAfriVac, has been given to millions of people in Africa's so-called "meningitis belt," and is about to be administered to even more. The World Health Organization approved the shot, previously approved for people aged one to 29, for use in the routine immunization of infants less than one year old in sub-Saharan Africa.